Literature DB >> 1358974

Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.

F Cavallo1, M Giovarelli, A Gulino, A Vacca, A Stoppacciaro, A Modesti, G Forni.   

Abstract

TS/A is a spontaneous adenocarcinoma, apparently not immunogenic in BALB/cnAnCr mice. TS/A cells are unable to stimulate a syngeneic antitumor response either in vitro or in vivo. To evaluate the immunogenic potential of IL-2-releasing neoplastic cells, we used an expression vector to introduce the cDNA coding for murine IL-2 into TS/A cells. Six clones releasing between 30 and 6800 U of IL-2/10(5) cells/ml/48 h have been isolated. Both low (30 U, B1.30) and high (6000 U, B4.6000) IL-2-releasing clone are capable of stimulating a proliferative and cytotoxic response in syngeneic cultures. While the B1.30 clone grows in 60% of syngeneic mice with a delayed pattern, the five clones that release higher levels of IL-2 are promptly rejected. Rejection is associated with neutrophil infiltration, the intensity of which is directly proportional to the amount of IL-2 released. NK cells and CD4+ lymphocytes are uninfluential, whereas CD8+ lymphocytes play only a minor role. This neutrophil-dominated rejection leaves a long-lasting, tumor-specific, T lymphocyte-mediated immune memory. For its induction, CD4+ lymphocytes are required. Their specific activation appears to depend on both the amount of IL-2 released and the granulocyte-mediated reaction that may lead to a more efficient presentation of tumor-associated Ag. These data support the notion that, after transduction of IL-2 gene, cancer cells may elicit an immune antitumor response, and stress the potential use of IL-2 as a component of new tumor vaccines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358974

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 2.  Melanoma vaccines. Current status and future prospects.

Authors:  P Hersey
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 3.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 4.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 5.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

6.  Cancer vaccines: the interleukin 2 dosage effect.

Authors:  W Schmidt; T Schweighoffer; E Herbst; G Maass; M Berger; F Schilcher; G Schaffner; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 7.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

Review 8.  Enhancement of anti-tumor immunity by photodynamic therapy.

Authors:  Sandra O Gollnick; Craig M Brackett
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

Review 9.  Strategies for cytokine utilisation in tumor therapy.

Authors:  F Di Pierro; F Cavallo; F Pericle; S Bertini; M Giovarelli; G Forni
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 10.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.